News
AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023
News
2024-07-23
AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer
2024-05-23
AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer
2023-11-16
Best Oncology R&D Advance Award went to AffyImmune Therapeutics, Inc.’s AIC100 ICAM-1 targeting CAR T cell therapy.
2023-05-25
AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Cl
2023-04-12
Thyroid Cancer Market to Grow at a Substantial Growth Rate, Predicts DelveInsight | Novartis, AffyImmune Therapeutics, Eli Lilly, Loxo Oncology, Bristol-Myers Squibb, and Others Expected to P
2022-05-02
Thyroid Cancer Pipeline Offers Promising New Options for Treatment | DelveInsight
2021-10-07
AffyImmune attracts $30M with its CAR-T strategy for beleaguered solid tumor cancers
2021-06-21
AffyImmune Therapeutics Announces Hiring of Matt Britz as Senior Vice President of Business Development
2021-06-15
AffyImmune Therapeutics Announces Addition of Dr. Jim Mulé to its Scientific Advisory Board
2021-05-25
AffyImmune Co-founder Dr. Moonsoo Jin Receives Highly Selective R01 Grant from NCI
2021-05-17
AffyImmune Therapeutics’ AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
2020-10-29
AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer
2020-06-29
AffyImmune Therapeutics presents novel CAR T development programs at the annual meeting of the American Association of Cancer Research
2019-10-30